Immune Pharmaceuticals CEO to Chair BIO International Panel "Can Israel Become the Next Biotech Startup Nation?"

Immune Pharmaceuticals CEO to Chair BIO International Panel "Can Israel Become
                      the Next Biotech Startup Nation?"

PR Newswire

HERZLIYA-PITUACH, Israel, April 23, 2013

HERZLIYA-PITUACH, Israel, April 23, 2013 /PRNewswire/ --Immune
Pharmaceuticals Ltd. ("Immune"), a privately held Israeli company, announced
today that the company's CEO Daniel Teper is the moderator of this morning's
BIO International Convention breakout session "Can Israel Become the Next
BioTech Startup Nation?" The panel, which will take place from 9:00 am – 9:45
amCT today at the conference in Chicago, IL, USA, will bring together life
science thought leaders to discuss high-tech innovation and biotech areas of
opportunity. Speakers at today's session include:

Ora Dar, Head of Life Sciences Office of the Chief Science at Israeli Ministry
of Industry Trade and Labor

Nissim Darvish, M.D., Ph.D., Senior Managing Director at Orbimed Advisors LLC

Nadav Kidron,CEO, Oramed Pharmaceuticals Inc.

Yaacov Michlin CEO, Yissum, the Technology Transfer Company of the Hebrew
University of Jerusalem

About the Panel (Building: S101A; International Market Briefings Track)

Israel has become a model for high tech entrepreneurship. A country of 8
million people, Israel is home to a vibrant academic biomedical research
sector, a global pharmaceutical company and several public biotech companies.
Yet, the success of Israel's biotech sector pales in comparison to its
high-tech industry. What can be learned from the Israeli Hi-tech Innovation
and Entrepreneurship model and how can it be applied to biotech? Which
regional partnerships can best leverage Israel's potential? What is the
optimal positioning for Israeli Biotech to encourage biopharma companies and
investors to step up their involvement? Complete panel information can be
found here.

About Immune Pharmaceuticals Ltd.

Immune Pharmaceuticals Ltd. is an Israel and U.S.-based biopharmaceutical
company focused on the treatment of inflammatory diseases and cancer. Immune
licensed worldwide rights for systemic indications of bertilimumab from iCo
Therapeutics (TSX: ICO) in June 2011, while iCo retained rights to all
ophthalmic indications. iCo originally licensed the exclusive world-wide
rights to bertilimumab in 2006 from Cambridge Antibody Technology Limited, now
part of MedImmune, the global biologics research and development arm of
AstraZeneca. Additionally, Immune has licensed from Yissum, the technology
transfer company of the Hebrew University of Jerusalem, the injectable
applications of the antibody nanoparticle conjugate technology (NanomAbs®).
For more information, visit www.immunepharmaceuticals.com.

SOURCE Immune Pharmaceuticals Ltd.

Website: http://www.immunepharmaceuticals.com
Contact: Anna Baran, Immune New York Office, Director, Corporate Development,
+1 (646) 937-1941, anna.baran@immunepharma.com; or Juda Engelmayer, 5W Public
Relations, +1 (212) 584-4272, jengelmayer@5wpr.com
 
Press spacebar to pause and continue. Press esc to stop.